@article{ref1,
title="Wishing to die or self-harm after stroke: a planned secondary analysis of the AFFINITY randomised controlled trial",
journal="Maturitas",
year="2022",
author="Almeida, Osvaldo P. and Hankey, Graeme J. and Ford, Andrew and Etherton-Beer, Christopher and Flicker, Leon and Hackett, Maree",
volume="166",
number="",
pages="86-88",
abstract="We investigated the cumulative prevalence of self-harm ideation among stroke survivors of the AFFINITY trial. We assessed these thoughts with the last item of the PHQ-9, and functional impairment with the modified Rankin Scale (mRS). Of 1221 participants (age 63.9 ± 12.3 years, 775 men), 11 reported wishing to die or self-harm at baseline. By week 52, 36 of 1159 surviving participants had reported wishing to die or self-harm. Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo. Clinically significant symptoms of depression were present in 95 % of participants with recurrent self-harm thoughts. The study was registered with the Australian and New Zealand Clinical Trials Registry, ACTRN12611000774921.<p /> <p>Language: en</p>",
language="en",
issn="0378-5122",
doi="10.1016/j.maturitas.2022.08.011",
url="http://dx.doi.org/10.1016/j.maturitas.2022.08.011"
}